Precision Medicine in Soft Tissue Sarcoma Treatment

Nakano, Kenji; Takahashi, Shunji

doi:10.3390/cancers12010221

Cited by 21 publications

(31 citation statements)

References 109 publications

(113 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, CIK cell-mediated immunotherapy can be contemplated synergistically with other immunotherapies, such as T cell checkpoint inhibitors, for example cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death-1 (PD-1) or its ligand (PDL-1). In fact, preclinical data suggest that combined therapy may be synergistic as CIK cells express PD-1 on their membrane [123,124]. The activity of this combination against CSCs should be addressed in future studies in STS.…”

Section: Directed Immunotherapymentioning

confidence: 99%

Cancer Stem Cells in Soft-Tissue Sarcomas

Martínez-Delgado

Lacerenza

Obrador‐Hevia

et al. 2020

Cells

View full text Add to dashboard Cite

Soft tissue sarcomas (STS) are a rare group of mesenchymal solid tumors with heterogeneous genetic profiles and clinical features. Systemic chemotherapy is the backbone treatment for advanced STS; however, STS frequently acquire resistance to standard therapies, which highlights the need to improve treatments and identify novel therapeutic targets. Increases in the knowledge of the molecular pathways that drive sarcomas have brought to light different molecular alterations that cause tumor initiation and progression. These findings have triggered a breakthrough of targeted therapies that are being assessed in clinical trials. Cancer stem cells (CSCs) exhibit mesenchymal stem cell (MSC) features and represent a subpopulation of tumor cells that play an important role in tumor progression, chemotherapy resistance, recurrence and metastasis. In fact, CSCs phenotypes have been identified in sarcomas, allied to drug resistance and tumorigenesis. Herein, we will review the published evidence of CSCs in STS, discussing the molecular characteristic of CSCs, the commonly used isolation techniques and the new possibilities of targeting CSCs as a way to improve STS treatment and consequently patient outcome.

show abstract

Section: Directed Immunotherapymentioning

confidence: 99%

Cancer Stem Cells in Soft-Tissue Sarcomas

Martínez-Delgado

Lacerenza

Obrador‐Hevia

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…Outcomes for those patients are poor, with an objective response rate (ORR) of about 14%, median progressive-free survival (PFS) of about 5 months and overall survival (OS) of 12 to 16 months. 2 , 3 Various cytotoxic drugs are being used as second-line treatment after failure of doxorubicin-based therapy, among these drugs is docetaxel plus gemcitabine as one of the most widely used therapy, with modest activity and significant hematological toxicity. 4 Other more commonly used for specific tumors are high-dose ifosfamide for synovial sarcoma, 5 paclitaxel for angiosarcoma, 6 and trabectedin for liposarcoma/leiomyosarcoma.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas

Li¹,

Yao²,

Zhao³

et al. 2021

CMAR

View full text Add to dashboard Cite

Purpose Anlotinib is a novel tyrosine kinase inhibitor with promising anti-tumor activity in patients with advanced soft tissue sarcomas (STS) in China. Liposomal doxorubicin monotherapy showed an encouraging effect on this disease. The aim of this study was to evaluate the efficacy and safety of anlotinib combined with liposomal doxorubicin followed by anlotinib maintenance in patients with metastatic STS. Patients and Methods This is a multicenter, retrospective, observational study. We reviewed 27 patients with metastatic STS from July 2018 to December 2019, who were treated with anlotinib combined with liposomal doxorubicin followed by anlotinib maintenance in the absence of the tumor progression or intolerable adverse events (AEs). Results Of the 27 patients included, 2 patients had complete response (CR), 9 patients obtained partial response (PR), 11 patients achieved stable disease (SD). The objective response rate was 40.7%, the disease control rate was 81.5%, and the median progression-free survival (PFS) was 7 months (95% CI, 5.3–8.1 months). The progression-free rate (PFR) at 3 and 6 months was 81.5% and 59.3%, respectively. Most AEs were mild and acceptable. The most frequent grade 3/4 AEs were leukopenia (33.3%), febrile neutropenia (7.4%), and anemia (7.4%). No deaths related to the treatment were reported. Conclusion This study shows that anlotinib combined with liposomal doxorubicin followed by anlotinib maintenance is effective in patients with metastatic STS, and most AEs of this combined therapy are mild and acceptable. Further investigation on its efficacy is warranted.

show abstract

“…In 2010, three new drugs for soft tissue sarcoma were approved based on the results of phase 3 trials, but the histological subtypes of the patients enrolled in the trials of each drug differed 85 …”

Section: Malignant Rptsmentioning

confidence: 99%

Retroperitoneal tumors: Review of diagnosis and management

Sassa

2020

Int J of Urology

View full text Add to dashboard Cite

Retroperitoneal tumors are extremely rare tumors occurring in the retroperitoneum. Retroperitoneal tumors are divided into benign tumors and malignant tumors, including retroperitoneal sarcoma. Approximately 70-80% of primary retroperitoneal soft-tissue tumors are malignant; however, these only account for 0.1-0.2% of all malignancies. Retroperitoneal sarcoma is an orphan malignant disease with a low incidence. The information on benign retroperitoneal tumors is limited. The American Joint Committee on Cancer/TNM classification updated to the 8th edition in 2017. In 2010, three new drugs for soft tissue sarcoma were approved based on the results of phase III trials, but the histological subtypes of the patients enrolled in the trials of each drug differed. Recently, in addition to surgery for retroperitoneal sarcoma, the effectiveness of perioperative radiation therapy has become interesting. For malignant retroperitoneal tumors and retroperitoneal sarcoma, survival improvement and locoregional recurrence prevention can be undertaken by carrying out surgery to secure negative margins with wide and combined resection of some adjacent organs, and cooperation with a trained medical team comprising of radiologists, pathologists and medical oncologists in centralized hospitals. Some clinical trials aimed at further improving treatment results by adding preoperative chemotherapy and radiation therapy based on histological confirmation using a correct needle biopsy are in progress. In recent years, molecular profiling has been used to select eligible patients for chemotherapy. In the future, precision medicine with next-generation sequencing technology will be expected among the diverse and potential future treatments for retroperitoneal sarcoma. In this review, we summarized the current state of retroperitoneal tumors and retroperitoneal sarcoma.

show abstract

Precision Medicine in Soft Tissue Sarcoma Treatment

Cited by 21 publications

References 109 publications

Cancer Stem Cells in Soft-Tissue Sarcomas

Cancer Stem Cells in Soft-Tissue Sarcomas

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas

Retroperitoneal tumors: Review of diagnosis and management

Contact Info

Product

Resources

About